Watch AMPH. Know when insiders buy.
One email the day a filing lands. Free.
Work order
38
FLAG · insiders 46, shorts 29
Insiders, 90 days
−$75K
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $986MP/E 13.7DIV YIELD —FCF YIELD 15.51%REV TTM $730M +1.0%NET INCOME $78.5M −41.7%NET CASH $183.3M52W 16.87 – 29.40SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $183.9M | +5.4% | 50.8% | $39.7M | $30.3M | −2.2% | 0.67 | $51.3M | $8.6M | $42.7M | Aug 6 |
| Q1 2026 · Mar 31 | $171.2M | +0.4% | 41.1% | $13.6M | $6.4M | −74.6% | 0.14 | $47.8M | $9.5M | $38.3M | Aug 6 |
| Q4 2025 · Dec 31derived | $183.1M | −1.8% | 46.8% | $35.6M | $24.4M | −35.7% | 0.51 | $32.9M | $8.3M | $24.6M | Feb 26 |
| Q3 2025 · Sep 30 | $191.8M | +0.3% | 51.4% | $25.3M | $17.4M | −57.1% | 0.37 | $52.6M | $5.3M | $47.2M | Nov 6 |
| Q2 2025 · Jun 30 | $174.4M | −4.4% | 49.6% | $42.2M | $31M | −18.2% | 0.64 | $35.6M | $10.6M | $25M | Aug 6 |
| Q1 2025 · Mar 31 | $170.5M | −0.8% | 50.0% | $37.3M | $25.3M | −41.4% | 0.51 | $35.1M | $10.7M | $24.4M | Aug 6 |
| Q4 2024 · Dec 31derived | $186.5M | +4.7% | 46.5% | $45.1M | $38M | +5.0% | 0.74 | $29M | $12.4M | $16.6M | Feb 26 |
| Q3 2024 · Sep 30 | $191.2M | +5.9% | 53.3% | $57M | $40.4M | −17.9% | 0.78 | $60M | $13.8M | $46.2M | Nov 6 |
| Q2 2024 · Jun 30 | $182.4M | — | 52.2% | $55.2M | $37.9M | — | 0.73 | $69.1M | $6M | $63.1M | Nov 6 |
| Q1 2024 · Mar 31 | $171.8M | — | 52.4% | $48M | $43.2M | — | 0.81 | $55.3M | $8.8M | $46.5M | Nov 6 |
| Q4 2023 · Dec 31derived | $178.1M | — | 54.0% | $54M | $36.2M | — | 0.69 | $23.9M | $9.4M | $14.4M | Feb 26 |
| Q3 2023 · Sep 30 | $180.6M | — | 60.0% | $72.7M | $49.2M | — | 0.91 | $64.3M | $10.2M | $54.1M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $719.9M | 49.5% | $140.4M | $98.1M | 13.6% | 2.03 | $156.1M | $34.9M | $121.2M | $75.6M | — |
| FY2024 · to Dec 31 | $732M | 51.1% | $205.4M | $159.5M | 21.8% | 3.06 | $213.4M | $41M | $172.3M | $85.5M | — |
| FY2023 · to Dec 31 | $644.4M | 54.5% | $197M | $137.5M | 21.3% | 2.60 | $183.5M | $38.2M | $145.3M | $58.1M | — |
| FY2022 · to Dec 31 | $499M | 49.9% | $107.5M | $91.4M | 18.3% | 1.74 | $89.2M | $24M | $65.1M | $39.9M | — |
| FY2021 · to Dec 31 | $437.8M | 45.6% | $69.9M | $62.1M | 14.2% | 1.25 | $98M | $27.5M | $70.5M | $28.9M | — |
| FY2020 · to Dec 31 | $349.8M | 41.0% | $11M | $1.4M | 0.4% | 0.03 | $57.3M | $33.9M | $23.4M | $24.4M | — |
Every number comes from Amphastar Pharmaceuticals, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.